Navigation Links
Nasulin Interim Results to Be Presented at American Diabetes,Association Scientific Sessions

EXETER, N.H.--(BUSINESS WIRE)--Apr 10, 2007 - Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical company, today announced that its abstract entitled "Interim Results of a Randomized, Single-Dose, 4-Way Crossover, Pharmacokinetic Study of Intranasal Insulin Spray (Nasulin(TM)), Injectable Regular Insulin (Humulin R(R)), Injectable Fast-Acting Insulin (Humalog(R)), and Saline Nasal Spray in Patients with Type I Diabetes Mellitus," has been selected for oral presentation at the American Diabetes Association 67th Scientific Sessions in Chicago. Dr. Sherwyn L. Schwartz, M.D., of dgd Research, Inc., will make the presentation as part of the first session on Friday, June 22, 2007.

Another Bentley sponsored study has also been accepted for a poster presentation in the category Clinical Therapeutics/New Technology - Insulin Delivery Systems. The poster abstract, "Intranasulin Insulin Spray (Nasulin(TM)) in Healthy Subjects: Choice of Nostril," will be displayed Saturday through Monday, June 23-25, 2007, in the General Poster Session in the Exhibit Hall.

Founded in 1979 by Dr. Schwartz, the Diabetes & Glandular Disease Clinic is the largest private endocrine clinic in the United States with over 70,000 active patients, eight board certified endocrinologists, seven NPs/PAs and an ADA recognized diabetes education program. The research arm, dgd Research Associates, Inc., has a staff of over 250 employees and has conducted over 1,500 Phase I through III clinical trials, primarily in targeted endocrine populations. Currently work is underway on construction of a new 80,000sq. ft. Phase I unit. For more information visit www.dgdclinic.com and www.dgdresearch.com.

Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and generic pharmaceutical products. Bentley's proprietary drug delivery technologies enhance the absorption of pha rmaceutical compounds across various membranes. Bentley manufactures and markets a growing portfolio of generic and branded generic pharmaceuticals in Europe for the treatment of cardiovascular, gastrointestinal, infectious and central nervous system diseases through its subsidiaries -- Laboratorios Belmac, Laboratorios Davur, Laboratorios Rimafar and Bentley Pharmaceuticals Ireland. Bentley also manufactures and markets active pharmaceutical ingredients through its subsidiary, Bentley API.

Additional information regarding Bentley Pharmaceuticals may be obtained through Bentley's web site at www.bentleypharm.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward looking statements, including without limitation, statements regarding plans for the announcement of interim results of a clinical trial of Bentley's intranasal insulin product candidate. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to risks associated with the efficacy and safety of Bentley's intranasal insulin product candidate and its drug delivery technology, risks associated with international clinical trials, and other risks detailed under Item 1A "Risk Factors" in Bentley's most recent Annual Report on Form 10-K and its subsequent periodic reports filed with the Securities and Exchange Commission. Bentley cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and Bentley undertakes no obligation to update or revise the statements, except as may be required by law.

Contact

Bentley Pharmaceuticals, Inc.
Jean DeRoche, 603-658-6136
jderoche@bentleypharm.com
or
Sharon Merrill Associates
James R. Buckley, 617-542-5300
Executive Vice President
bnt@investorrelations.com


'"/>




Related medicine technology :

1. Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
8. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
9. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
10. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
11. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Nov. 29, 2016 Several leading Alzheimer,s ... Accera, Inc. at 11 a.m. EST on ... Conference on Clinical Trials for Alzheimer,s Disease (CTAD). The ... in Alzheimer,s disease and therapeutic targets that address deficient ... "Following the recent failure of another therapy targeting the ...
(Date:12/5/2016)... , Dec 5, 2016 Research ... Market by Product (Instruments, Consumables), Application (Biomedical & Biochemical Research, Disease ... - Global Forecasts to 2021" report to their offering. ... , , ... USD 730.7 Million in 2021 from USD 574.8 Million in 2016, ...
(Date:12/5/2016)... PUNE, India , December 5, 2016 ... Market by Product Type and by Application - Global Opportunity Analysis and Industry ... in 2015, and is expected to reach $5,255 million by 2022, growing at ... market in 2015 with more than four-fifths share. ... ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... 06, 2016 , ... The Behavioral Health Center of Excellence ... organization as a top behavioral service provider in the country. The award celebrates ... satisfaction and qualifications, and consumer satisfaction. These areas are measured via a wide-ranging ...
(Date:12/6/2016)... ... December 06, 2016 , ... Experimentation involving human stem ... largely due to its potential for revolutionizing human disease treatment. There are multiple ... pluripotent stem cells (hiPSCs). , Both platforms have distinct advantages and disadvantages, ...
(Date:12/6/2016)... ... 06, 2016 , ... METTLER TOLEDO has launched its online ... white papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, brochures, datasheets, user ... documents, webinars and videos available online, visit the METTLER TOLEDO Expertise Library ...
(Date:12/6/2016)... ... ... 'Tis the season for family, festivity, food and fun! Temptation abounds, and ... eating healthy, staying active, and taking medication and doing daily foot health checks (a ... "Shopping trips, parties and family gatherings can take their toll on our feet during ...
(Date:12/6/2016)... B.C., Canada (PRWEB) , ... December 06, 2016 ... ... (STC) announce the availability of the newly updated International Audit Protocol Consortium (IAPC) ... use IAPC EHS audit protocols to understand the scope of their EHS regulatory ...
Breaking Medicine News(10 mins):